Colorectal Cancer Market

 Market Overview:

The 7 major colorectal cancer markets reached a value of US$ 13.6 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 17.3 Billion by 2034, exhibiting a growth rate (CAGR) of 2.22% during 2024-2034.

The colorectal cancer market has been comprehensively analyzed in IMARC's new report titled "Colorectal Cancer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Colorectal cancer develops in the colon or rectum; depending on where they start, these malignancies are known as colon or rectal cancer. Since they have many common characteristics, colon and rectal cancers are sometimes grouped together. A majority of colorectal cancers begin as a growth on the interior lining of the colon or rectum, also known as polyps. Some common symptoms of colorectal cancer include changes in bowel patterns, such as constipation or diarrhea that lasts more than a few days, blood in the stool or rectal bleeding, stomach discomfort or cramping, etc. Other symptoms are unexplained weight loss, fatigue or weakness, a lump or mass in the abdomen, and an unusually low number of red blood cells. The diagnosis of colorectal cancer typically involves a combination of tests, including a rectal exam, colonoscopy, sigmoidoscopy, biopsy, stool DNA, CT colonography, barium enema X-ray imaging tests, such as CT scan and MRI, etc. The treatment options include surgery, radiation therapy, and chemotherapy. A combination of these therapies may be employed in some circumstances.

The escalating incidences of polyps or inflammatory bowel diseases, such as Crohn's disease or ulcerative colitis, are primarily driving the global colorectal cancer market. In addition to this, the rising prevalence of several associated risk factors, including smoking, alcohol consumption, taking a diet high in red or processed meats, etc., which increase the likelihood of developing colorectal cancer, is also bolstering the market growth. Furthermore, the growing awareness regarding the early detection of colorectal cancer since it can enhance the chances of survival is creating a positive outlook for the market. Numerous screening tests, including stool-based tests and virtual colonoscopies, etc., are widely available to help detect colorectal cancer at an early stage. Besides this, the widespread adoption of combination therapy for improving treatment outcomes and reducing the risk of cancer relapse is also propelling the market growth. Moreover, the emerging popularity of precision medicine, which involves tailoring treatment to the specific genetic makeup of a person's tumor, thereby allowing for more targeted and effective treatment, is acting as another significant growth-inducing factor. Apart from this, the rising popularity of complementary and alternative therapies, such as acupuncture and herbal medicine, to help manage the side effects of colorectal cancer treatment and improve overall well-being is expected to drive the global colorectal cancer market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the colorectal cancer market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for colorectal cancer and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the colorectal cancer market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the colorectal cancer market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the colorectal cancer market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current colorectal cancer marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the colorectal cancer market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the colorectal cancer market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the colorectal cancer market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of colorectal cancer across the seven major markets?
• What is the number of prevalent cases (2018-2034) of colorectal cancer by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of colorectal cancer by gender across the seven major markets?
• What is the number of prevalent cases (2018-2034) of colorectal cancer by type across the seven major markets?
• How many patients are diagnosed (2018-2034) with colorectal cancer across the seven major markets?
• What is the size of the colorectal cancer patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of colorectal cancer?
• What will be the growth rate of patients across the seven major markets?
   

Colorectal Cancer: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for colorectal cancer drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the colorectal cancer market?
• What are the key regulatory events related to the colorectal cancer market?
• What is the structure of clinical trial landscape by status related to the colorectal cancer market?
• What is the structure of clinical trial landscape by phase related to the colorectal cancer market?
• What is the structure of clinical trial landscape by route of administration related to the colorectal cancer market?